Histopathologic review of suspected disease progression in patients with recurrent glioblastoma (GBM) receiving nivolumab +/- ipilimumab: CheckMate 143. Sahebjam, S., Ramkissoon, S., Baehring, J. M., Mulholland, P., Grauer, O. M., Cloughesy, T., Reardon, D. A., Lim, M., Zwirtes, R. F., Latek, R., Strauss, L. C., Ligon, K. L. AMER SOC CLINICAL ONCOLOGY. 2017

View details for DOI 10.1200/JCO.2017.35.15_suppl.2001

View details for Web of Science ID 000411895703171